Poop pills could tame rare liver disease

NCT ID NCT06286709

First seen May 02, 2026 · Last updated May 16, 2026 · Updated 2 times

Summary

This study tests whether a fecal microbiota transplant (FMT) can improve liver health in people with primary sclerosing cholangitis (PSC) and inflammatory bowel disease. About 58 adults will receive either FMT or a placebo. The main goal is to see if FMT lowers a key liver enzyme over 48 weeks.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PRIMARY SCLEROSING CHOLANGITIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • John Radcliffe Hospital, Oxford University Hospitals NHS Foundation Trust

    RECRUITING

    Oxford, OX3 9DU, United Kingdom

    Contact

  • King's College Hospital, King's College Hospital NHS Foundation Trust

    RECRUITING

    London, SE5 9RS, United Kingdom

    Contact

  • Queen Elizabeth Hospital Birmingham, University Hospitals Birmingham NHS Foundation Trust

    RECRUITING

    Birmingham, B15 2TH, United Kingdom

    Contact

  • Royal Free Hospital, Royal Free London NHS Foundation Trust

    RECRUITING

    London, NW3 2QG, United Kingdom

    Contact

  • St Mark's Hospital, London North West University Healthcare NHS Trust

    RECRUITING

    London, NW10 7NS, United Kingdom

    Contact

Conditions

Explore the condition pages connected to this study.